30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Better Therapeutics Inc (BTTX)

Track

Stock chart
Ticker: BTTX Exchange: PNK
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
KARBE FRANK
Chief Executive Officer
1 purchase — total 100,000 USD
Buy 27 Jul 2023
Value US$2,997,331.40 | Price 283.98 | Shares 27,829
Buy 27 Jul 2023
Value US$3,838,388.23 | Price 249.12 | Shares 24,975
Buy 27 Jul 2023
Value US$499,999.75 | Price 0.73 | Shares 685,025
Buy 27 Jul 2023
Value US$24,999.80 | Price 0.73 | Shares 34,251
Buy 27 Jul 2023
Value US$199,999.90 | Price 0.73 | Shares 274,010
Buy 27 Jul 2023
Value US$39,999.98 | Price 0.73 | Shares 54,802
Buy 16 May 2023
Value US$520.32 | Price 0.87 | Shares 600
Buy 10 Apr 2023
Value US$249,999.75 | Price 0.83 | Shares 303,030
Buy 10 Apr 2023
Value US$249,999.75 | Price 0.83 | Shares 303,030
Buy 10 Apr 2023
Value US$199,999.80 | Price 0.83 | Shares 242,424
Buy 10 Apr 2023
Value US$3,000,000.30 | Price 0.83 | Shares 3,636,364
Buy 10 Apr 2023
Value US$1,099,999.72 | Price 0.83 | Shares 1,333,333
Buy 16 Sep 2022
Value US$80,974.61 | Price 2.07 | Shares 39,156
Buy 15 Sep 2022
Value US$21,622.94 | Price 1.99 | Shares 10,844
Buy 15 Sep 2022
Value US$104,695.00 | Price 2.09 | Shares 50,000
Buy 13 Sep 2022
Value US$50,696.08 | Price 1.94 | Shares 26,132
Buy 12 Sep 2022
Value US$46,303.92 | Price 1.94 | Shares 23,868
Buy 24 Jun 2022
Value US$3,999.95 | Price 1.75 | Shares 2,281
Buy 14 Jun 2022
Value US$20,845.50 | Price 1.39 | Shares 15,000
Buy 13 Jun 2022
Value US$36,182.50 | Price 1.45 | Shares 25,000
Buy 10 Jun 2022
Value US$7,800.00 | Price 1.56 | Shares 5,000
Buy 9 Jun 2022
Value US$41,355.00 | Price 1.65 | Shares 25,000
Buy 31 Mar 2022
Value US$4,921.25 | Price 1.97 | Shares 2,500
Buy 31 Mar 2022
Value US$9,900.00 | Price 1.98 | Shares 5,000
Buy 21 Dec 2021
Value US$46,000.00 | Price 4.60 | Shares 10,000
Buy 20 Dec 2021
Value US$4,599.90 | Price 4.60 | Shares 1,000
Buy 15 Dec 2021
Value US$3,529.88 | Price 4.71 | Shares 750
Buy 15 Dec 2021
Value US$10,953.44 | Price 4.70 | Shares 2,333
Buy 14 Dec 2021
Value US$98,800.00 | Price 4.94 | Shares 20,000
Buy 14 Dec 2021
Value US$2,721.20 | Price 5.44 | Shares 500
Buy 13 Dec 2021
Value US$2,725.00 | Price 5.45 | Shares 500
Buy 13 Dec 2021
Value US$115,067.40 | Price 5.48 | Shares 21,000
Buy 10 Dec 2021
Value US$5,975.20 | Price 5.98 | Shares 1,000
Buy 3 Dec 2021
Value US$6,660.00 | Price 6.66 | Shares 1,000
Buy 3 Dec 2021
Value US$3,213.00 | Price 6.43 | Shares 500
Buy 2 Dec 2021
Value US$3,420.00 | Price 6.84 | Shares 500
Buy 29 Nov 2021
Value US$118,320.00 | Price 6.96 | Shares 17,000
Buy 28 Oct 2021
Value US$2,000,000.00 | Price 10.00 | Shares 200,000
Buy 26 May 2021
Value US$199,000.00 | Price 9.95 | Shares 20,000
Buy 24 May 2021
Value US$79,520.00 | Price 9.94 | Shares 8,000
Buy 21 May 2021
Value US$79,600.00 | Price 9.95 | Shares 8,000
Buy 14 May 2021
Value US$30,385.80 | Price 9.93 | Shares 3,060
Buy 13 May 2021
Value US$69,510.00 | Price 9.93 | Shares 7,000
Buy 4 May 2021
Value US$34,516.68 | Price 9.93 | Shares 3,476
Buy 30 Apr 2021
Value US$19,900.00 | Price 9.95 | Shares 2,000
Sale 7 Apr 2021
Value US$1,800,000.00 | Price 9.00 | Shares 200,000
Buy 14 Jan 2021
Value US$75,000.00 | Price 10.00 | Shares 7,500
Buy 14 Jan 2021
Value US$75,000.00 | Price 10.00 | Shares 7,500
Buy 14 Jan 2021
Value US$75,000.00 | Price 10.00 | Shares 7,500
Buy 12 Jan 2021
Value US$1,350,000.00 | Price 10.00 | Shares 135,000
Buy 12 Jan 2021
Value US$1,350,000.00 | Price 10.00 | Shares 135,000
Buy 12 Jan 2021
Value US$1,350,000.00 | Price 10.00 | Shares 135,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-07-31 2023-07-27 B Purchase
1.2
KARBE FRANK

Chief Executive Officer

Executive Director
27,829 -25.2%
283.98
US$2,997,331 		27,829 -25.2% 283.98 US$2,997,331
2023-07-31 2023-07-27 B Purchase
1.5
PERRY DAVID P

Executive Chairman

Executive Director Large shareholder
24,975 -6.1%
249.12
US$3,838,388 		24,975 -6.1% 249.12 US$3,838,388
2023-07-31 2023-07-27 B Purchase
1.9
Parker Geoffrey M.
Non-Executive Director
27,425 +31.0%
455.18
US$781,689 		27,425 +31.0% 455.18 US$781,689
2023-07-31 2023-07-27 B Purchase
Granger Elder
Non-Executive Director
34,251 +2140.7%
0.73
US$25,000 		34,251 +2140.7% 0.73 US$25,000
2023-07-31 2023-07-27 B Purchase
3.4
Armanino Andrew J.
Non-Executive Director
274,010 +60.3%
0.73
US$200,000 		274,010 +60.3% 0.73 US$200,000
2023-07-31 2023-07-27 B Purchase
Berman Mark A.

Chief Medical Officer

Officer
54,802 +16.4%
0.73
US$40,000 		54,802 +16.4% 0.73 US$40,000
2023-05-18 2023-05-16 B Purchase
Granger Elder
Non-Executive Director
600 +60.0%
0.87
US$520 		600 +60.0% 0.87 US$520
2023-04-12 2023-04-10 B Purchase
3.4
Armanino Andrew J.
Non-Executive Director
303,030 +200.2%
0.83
US$250,000 		303,030 +200.2% 0.83 US$250,000
2023-04-12 2023-04-10 B Purchase
1.9
Parker Geoffrey M.
Non-Executive Director
303,030 +757.6%
0.83
US$250,000 		303,030 +757.6% 0.83 US$250,000
2023-04-12 2023-04-10 B Purchase
1.2
KARBE FRANK

See Remarks

Executive Director
242,424 +484.8%
0.83
US$200,000 		242,424 +484.8% 0.83 US$200,000
2023-04-12 2023-04-10 B Purchase
1.5
PERRY DAVID P

See Remarks

Executive Director Large shareholder
3,636,364 +inf%
0.83
US$3,000,000 		3,636,364 +inf% 0.83 US$3,000,000
2023-04-12 2023-04-10 B Purchase
1.5
PERRY DAVID P

See Remarks

Executive Director Large shareholder
1,333,333 +12.7%
0.83
US$1,100,000 		1,333,333 +12.7% 0.83 US$1,100,000
2022-09-19 2022-09-16 B Purchase
1.5
PERRY DAVID P

See Remarks

Executive Director Large shareholder
39,156 +62.8%
2.07
US$80,975 		39,156 +62.8% 2.07 US$80,975
2022-09-19 2022-09-15 B Purchase
1.5
PERRY DAVID P

See Remarks

Executive Director Large shareholder
10,844 +21.0%
1.99
US$21,623 		10,844 +21.0% 1.99 US$21,623
2022-09-15 2022-09-15 B Purchase
1.2
KARBE FRANK

See Remarks

Executive Director
50,000 +inf%
2.09
US$104,695 		50,000 +inf% 2.09 US$104,695
2022-09-14 2022-09-13 B Purchase
0.5
Heinen Mark

See Remarks

Officer
26,132 +59.6%
1.94
US$50,696 		26,132 +59.6% 1.94 US$50,696
2022-09-14 2022-09-12 B Purchase
0.5
Heinen Mark

See Remarks

Officer
23,868 +119.3%
1.94
US$46,304 		23,868 +119.3% 1.94 US$46,304
2022-06-28 2022-06-24 B Purchase
0.5
Heinen Mark

See Remarks

Officer
2,281 +inf%
1.75
US$4,000 		2,281 +inf% 1.75 US$4,000
2022-06-16 2022-06-14 B Purchase
3.4
Armanino Andrew J.
Non-Executive Director
15,000 +inf%
1.39
US$20,846 		15,000 +inf% 1.39 US$20,846
2022-06-14 2022-06-13 B Purchase
1.9
Parker Geoffrey M.
Non-Executive Director
25,000 +166.7%
1.45
US$36,182 		25,000 +166.7% 1.45 US$36,182
2022-06-10 2022-06-10 B Purchase
0.5
Heinen Mark

See Remarks

Officer
5,000 +33.3%
1.56
US$7,800 		5,000 +33.3% 1.56 US$7,800
2022-06-10 2022-06-09 B Purchase
3.4
Armanino Andrew J.
Non-Executive Director
25,000 +19.8%
1.65
US$41,355 		25,000 +19.8% 1.65 US$41,355
2022-04-04 2022-03-31 B Purchase
Appelbaum Kevin J

Chief Executive Officer

Executive Director Large shareholder
2,500 +66.7%
1.97
US$4,921 		2,500 +66.7% 1.97 US$4,921
2022-04-04 2022-03-31 B Purchase
0.5
Heinen Mark

See Remarks

Officer
5,000 +50.0%
1.98
US$9,900 		5,000 +50.0% 1.98 US$9,900
2021-12-23 2021-12-21 B Purchase
2.7
LAVIZZO-MOUREY RISA J
Non-Executive Director
10,000 +inf%
4.60
US$46,000 		10,000 +inf% 4.60 US$46,000
2021-12-22 2021-12-20 B Purchase
Appelbaum Kevin J

Chief Executive Officer

Executive Director Large shareholder
1,000 +36.4%
4.60
US$4,600 		1,000 +36.4% 4.60 US$4,600
2021-12-17 2021-12-15 B Purchase
Appelbaum Kevin J

Chief Executive Officer

Executive Director Large shareholder
750 +37.5%
4.71
US$3,530 		750 +37.5% 4.71 US$3,530
2021-12-15 2021-12-15 B Purchase
0.5
Heinen Mark

See Remarks

Officer
2,333 +30.4%
4.70
US$10,953 		2,333 +30.4% 4.70 US$10,953
2021-12-16 2021-12-14 B Purchase
1.9
Parker Geoffrey M.
Non-Executive Director
20,000 +60.0%
4.94
US$98,800 		20,000 +60.0% 4.94 US$98,800
2021-12-15 2021-12-14 B Purchase
0.5
Heinen Mark

See Remarks

Officer
500 +7.0%
5.44
US$2,721 		500 +7.0% 5.44 US$2,721
2021-12-15 2021-12-13 B Purchase
0.5
Heinen Mark

See Remarks

Officer
500 +7.5%
5.45
US$2,725 		500 +7.5% 5.45 US$2,725
2021-12-15 2021-12-13 B Purchase
3.4
Armanino Andrew J.
Non-Executive Director
21,000 +32.1%
5.48
US$115,067 		21,000 +32.1% 5.48 US$115,067
2021-12-14 2021-12-10 B Purchase
Appelbaum Kevin J

Chief Executive Officer

Executive Director Large shareholder
1,000 +100.0%
5.98
US$5,975 		1,000 +100.0% 5.98 US$5,975
2021-12-07 2021-12-03 B Purchase
Granger Elder
Non-Executive Director
1,000 +inf%
6.66
US$6,660 		1,000 +inf% 6.66 US$6,660
2021-12-06 2021-12-03 B Purchase
Appelbaum Kevin J

Chief Executive Officer

Executive Director Large shareholder
500 +100.0%
6.43
US$3,213 		500 +100.0% 6.43 US$3,213
2021-12-06 2021-12-02 B Purchase
Appelbaum Kevin J

Chief Executive Officer

Executive Director Large shareholder
500 +inf%
6.84
US$3,420 		500 +inf% 6.84 US$3,420
2021-12-01 2021-11-29 B Purchase
3.4
Armanino Andrew J.
Non-Executive Director
17,000 +35.2%
6.96
US$118,320 		17,000 +35.2% 6.96 US$118,320
2021-11-01 2021-10-28 B Purchase
1.5
PERRY DAVID P

See Remarks

Executive Director Large shareholder
200,000 +1.9%
10.00
US$2,000,000 		200,000 +1.9% 10.00 US$2,000,000
2021-11-01 2021-05-26 B Purchase
1.5
PERRY DAVID P

See Remarks

Executive Director Large shareholder
20,000 +63.4%
9.95
US$199,000 		20,000 +63.4% 9.95 US$199,000
2021-11-01 2021-05-24 B Purchase
1.5
PERRY DAVID P

See Remarks

Executive Director Large shareholder
8,000 +34.0%
9.94
US$79,520 		8,000 +34.0% 9.94 US$79,520
2021-11-01 2021-05-21 B Purchase
1.5
PERRY DAVID P

See Remarks

Executive Director Large shareholder
8,000 +51.5%
9.95
US$79,600 		8,000 +51.5% 9.95 US$79,600
2021-11-01 2021-05-14 B Purchase
1.5
PERRY DAVID P

See Remarks

Executive Director Large shareholder
3,060 +24.5%
9.93
US$30,386 		3,060 +24.5% 9.93 US$30,386
2021-11-01 2021-05-13 B Purchase
1.5
PERRY DAVID P

See Remarks

Executive Director Large shareholder
7,000 +127.8%
9.93
US$69,510 		7,000 +127.8% 9.93 US$69,510
2021-11-01 2021-05-04 B Purchase
1.5
PERRY DAVID P

See Remarks

Executive Director Large shareholder
3,476 +173.8%
9.93
US$34,517 		3,476 +173.8% 9.93 US$34,517
2021-11-01 2021-04-30 B Purchase
1.5
PERRY DAVID P

See Remarks

Executive Director Large shareholder
2,000 +inf%
9.95
US$19,900 		2,000 +inf% 9.95 US$19,900
2021-04-09 2021-04-07 S Sale
1.9
Liu Suying

Chief Executive Officer

Executive Director Large shareholder
200,000 -12.7%
9.00
US$1,800,000 		200,000 -12.7% 9.00 US$1,800,000
2021-01-19 2021-01-14 B Purchase
2.6
Liu Dong

Chief Financial Officer

Executive Director Large shareholder
7,500 +0.5%
10.00
US$75,000 		7,500 +0.5% 10.00 US$75,000
2021-01-19 2021-01-14 B Purchase
1.9
Liu Suying

Chief Executive Officer

Executive Director Large shareholder
7,500 +0.5%
10.00
US$75,000 		7,500 +0.5% 10.00 US$75,000
2021-01-19 2021-01-14 B Purchase
2.0
Mountain Crest Capital LLC
Large shareholder
7,500 +0.5%
10.00
US$75,000 		7,500 +0.5% 10.00 US$75,000
2021-01-14 2021-01-12 B Purchase
1.9
Liu Suying

Chief Executive Officer

Executive Director Large shareholder
135,000 +9.4%
10.00
US$1,350,000 		135,000 +9.4% 10.00 US$1,350,000
2021-01-14 2021-01-12 B Purchase
2.6
Liu Dong

Chief Financial Officer

Executive Director Large shareholder
135,000 +9.4%
10.00
US$1,350,000 		135,000 +9.4% 10.00 US$1,350,000
2021-01-14 2021-01-12 B Purchase
2.0
Mountain Crest Capital LLC
Large shareholder
135,000 +9.4%
10.00
US$1,350,000 		135,000 +9.4% 10.00 US$1,350,000
Explore more

More insider trading research around Better Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America